Drug intelligence / Profile preview

rz602

Development stage: Preclinical
Lead developer: Rezolute
Modality: Small Molecules

Overview

RZ602 is a small molecule drug initially developed by Rezolute for the treatment of hereditary angioedema[7][9][14]. There is no publicly available detailed description of its mechanism of action, structure, or clinical profile beyond its target indication and company of origin. Unlike its counterpart RZ402 (a plasma kallikrein inhibitor for diabetic macular edema), there is no evidence that RZ602 is a kallikrein inhibitor or is being developed for retinal disease. No clinical trial data or detailed pharmacology information is publicly accessible for RZ602.

Beyond the preview

Go deeper on rz602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rz602.

Explore the full profile